UCB will present additional studies and data analyses highlighting UCB's ongoing commitment to improving outcomes for people living with gMG Two studies assessed the bioequivalence and effectiveness of zilucoplan auto-injector (ZLP-AI) administration compared with pre-filled syringe (ZLP-PFS)1 UCB is presenting 21 abstracts in total from its innovative neurology portfolio including 14 epilepsy abstracts and six myasthenia gravis (MG) abstracts at AAN 2026 April 13, 2026 -- UCB, a global biophar

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults The latest approval expands Dupixent’s indication for CSU in the EU to children as young as two years;

April 10, 2026 - Apotex Corp. today announced it has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection, marking a significant milestone in expanding affordable access to complex peptide therapies for patients across the United States. This approval reinforces Apotex's leadership in bringing high value, technically challenging medicines that help improve patient access and support a more sustain

16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults April 10, 2026 --MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase 1

April 10, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application (NDA) for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis (AD), has been formally accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This acceptance marks

The company has enrolled 10 patients, marking early momentum in evaluating a novel, non-invasive, drug-centered therapeutic approach to brain cancer treatment. April 9, 2026 -- Alpheus Medical, Inc., a private, clinical-stage biotechnology company, today announced the initiation of its Phase 2b randomized controlled trial in newly diagnosed glioblastoma (nGBM) with 10 patients enrolled to date and additional clinical sites continuing to come online. Glioblastoma is a highly infiltrative brain

GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to re application, pointing to its potential to treat cerebral folate deficiency with “autistic features.” GSK has withdrawn an approval application for Wellcovorin, a decades-old drug that late last year gained renewed attention after the members of the Trump administration publicly suggested it has the potential to treat autism symptoms. The pharma requested to terminate the new drug application because

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. April 07, 2026 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (rem

First-in-class TET2 activator targets DNA damage response in GBM and other cancers Strong preclinical efficacy, brain penetration, and safety pro clinical advancement Study led by world-leading glioblastoma investigators, including Dr. Roger Stupp Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and ot

April 7, 2026 -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in their clinical study evaluating spevatamig in combination with chemotherapy for the treatment of biliary tract cancer (BTC), following dose-limiting toxicity (DLT) clearance at two dose levels. Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin